目的: 探究新型冠状病毒肺炎（COVID-19）患者的药物治疗情况与药学监护重点,为临床 COVID-19 的治疗提供参考。方法 以 2020 年 3 月 10 日前遂宁市发现的 17 例 COVID-19 确诊患者作为研究对象,分析患者的用药状况和药物不良反应的监护及其转归等情况。结果 17 例 COVID-19 患者在定点医院经治疗后均痊愈出院,但重型患者的住院时间明显长于普通型和轻型患者;在药物治疗方面,所有患者均接受了抗病毒药物和中成药的治疗,16 例患者因合并有感染症状还使用了抗菌药物;在治疗过程中,有 15 例患者出现了以高脂血症、腹泻、恶心等为症状的药物不良反应,综合考虑不良反应发生与用药的时间关系,怀疑这些不良反应很可能均是由洛匹那韦-利托那韦所引起,但多数不良反应症状在对症处理后均消失或好转。结论 COVID-19 患者在定点医院医护人员的积极救治下均痊愈出院,但也发现不少患者在用药过程中出现不同程度的药物不良反应,临床应优化品种选择,同时加强对治疗用药的药学监护,以减少或避免药物不良反应发生。

Objective: To investigate the drug therapy and pharmaceutical care of patients with COVID-19 and provide reference for the clinical treatment of COVID-19. Methods: A total of 17 patients confirmed with COVID-19 in Suining City before March 10, 2020 were selected as subjects, to analyze the medication and monitoring of adverse drug reactions of the patients and their outcomes. Results: A total of 17 patients with COVID-19 were cured and discharged after treatment in designated hospitals, but the length of hospital stay of severe patients was significantly longer than that of ordinary and mild patients; in terms of drug therapy, all patients received the treatment with antiviral drugs and Chinese patent medicines, and 16 patients also received treatment with antibacterials due to concurrent infection symptoms; during the treatment, 15 patients developed adverse drug reactions with symptoms such as hyperlipidemia, diarrhea, nausea, etc. By considering the relationship between the occurrence of adverse reactions and medication time, it was suspected that these adverse reactions were probably caused by lopinavir-ritonavir, but most of them disappeared or improved after symptomatic treatment. Conclusion: All the patients with COVID-19 are cured and discharged under the active treatment by medical staff in the designated hospitals, but many patients were found to have different degrees of adverse drug reactions during the medication process. Clinically, it is necessary to optimize the selection of drugs and strengthen the pharmaceutical care of therapeutic drugs, to reduce or avoid the occurrence of adverse drug reactions.